In my mind , the fda needs to find a half way point with Cytodyn on how to look at the data or what the steps are to move forward. It still supports the theory that this was not a failure .it may have been a borderline which, based on the FDAs own definition of an EUA, (safety and some form of efficacy) should quality for EUA but they may want to do some additional review after initiating an EUA to support an outright approval